Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
12
07
2021
accepted:
25
10
2021
revised:
18
10
2021
pubmed:
10
11
2021
medline:
26
4
2022
entrez:
9
11
2021
Statut:
ppublish
Résumé
Obesity is among the main determinants of nonalcoholic fatty liver disease progression towards severe liver disease (SLD). However, risk factors for SLD in individuals with obesity have not been examined. To identify the independent risk factors for SLD among participants with obesity from the UK Biobank. A total of 80,224 UK Biobank participants with obesity (body mass index[BMI] > 30 kg/m Obesity conferred a 2.6-fold increased risk for SLD that was abolished after the inclusion of waist circumference (WC) in the model. Among individuals with obesity, age (adjusted hazard ratio [aHR] 1.05, 95%CI 1.03-1.07, p = 3.9 * 10 Age, WC, type 2 diabetes, and the PNPLA3 variant are the main risk factors for SLD in individuals with obesity. WC is the principal mediator of SLD risk conveyed by increased BMI. BMI category-specific WC-thresholds may refine the SLD risk more accurately than traditional thresholds.
Sections du résumé
BACKGROUND
Obesity is among the main determinants of nonalcoholic fatty liver disease progression towards severe liver disease (SLD). However, risk factors for SLD in individuals with obesity have not been examined.
OBJECTIVES
To identify the independent risk factors for SLD among participants with obesity from the UK Biobank.
METHODS
A total of 80,224 UK Biobank participants with obesity (body mass index[BMI] > 30 kg/m
RESULTS
Obesity conferred a 2.6-fold increased risk for SLD that was abolished after the inclusion of waist circumference (WC) in the model. Among individuals with obesity, age (adjusted hazard ratio [aHR] 1.05, 95%CI 1.03-1.07, p = 3.9 * 10
CONCLUSIONS
Age, WC, type 2 diabetes, and the PNPLA3 variant are the main risk factors for SLD in individuals with obesity. WC is the principal mediator of SLD risk conveyed by increased BMI. BMI category-specific WC-thresholds may refine the SLD risk more accurately than traditional thresholds.
Identifiants
pubmed: 34750514
doi: 10.1038/s41366-021-01015-w
pii: 10.1038/s41366-021-01015-w
pmc: PMC8573310
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-493Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
doi: 10.1038/nrgastro.2017.109
European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.
Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–7.
doi: 10.7326/0003-4819-132-2-200001180-00004
Berg EHvanden, Amini M, Schreuder TCMA, Dullaart RPF, Faber KN, Alizadeh, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: a large Dutch population cohort. PLOS ONE. 2017;12:e0171502.
doi: 10.1371/journal.pone.0171502
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.
doi: 10.1053/j.gastro.2010.09.038
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017–25.
doi: 10.1016/j.metabol.2016.01.012
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.
doi: 10.1002/hep.1840110114
Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:16–25.
doi: 10.1111/apt.14401
Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150–5.
doi: 10.1053/jhep.2002.33713
Finucane MM, Stevens GA, Cowan M, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.
doi: 10.1016/S0140-6736(10)62037-5
Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51–60.
doi: 10.1016/j.metabol.2018.11.009
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.
doi: 10.1053/jhep.2003.50229
Jacobs EJ, Newton CC, Wang Y, Patel AV, McCullough ML, Campbell PT, et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med. 2010;170:1293–301.
doi: 10.1001/archinternmed.2010.201
Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3:280–7.
doi: 10.1001/jamacardio.2018.0022
Ardern CI, Janssen I, Ross R, Katzmarzyk PT. Development of health-related waist circumference thresholds within BMI categories. Obes Res. 2004;12:1094–103.
doi: 10.1038/oby.2004.137
Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020;16:177–89.
doi: 10.1038/s41574-019-0310-7
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015 Mar;12:e1001779.
doi: 10.1371/journal.pmed.1001779
Elliott P, Peakman TC. UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37:234–44.
doi: 10.1093/ije/dym276
Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–9.
doi: 10.1038/s41586-018-0579-z
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223–238. https://doi.org/10.1038/s41575-020-00381-6 .
doi: 10.1038/s41575-020-00381-6
pubmed: 33349658
Björkström K, Franzén S, Eliasson B, Miftaraj M, Gudbjörnsdottir S, Trolle-Lagerros Y, et al. Risk factors for severe liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2019;17:2769–2775.e4.
doi: 10.1016/j.cgh.2019.04.038
Tavaglione F, De Vincentis A, Jamialahmadi O, Pujia R, Spagnuolo R, Picardi A, et al. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Rep. 2021;100262.
Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20.
doi: 10.1056/NEJMoa0801891
Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami H-O, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 2014;89:335–45.
doi: 10.1016/j.mayocp.2013.11.011
Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117:1658–67.
doi: 10.1161/CIRCULATIONAHA.107.739714
Song X, Jousilahti P, Stehouwer CDA, Söderberg S, Onat A, Laatikainen T, et al. Comparison of various surrogate obesity indicators as predictors of cardiovascular mortality in four European populations. Eur J Clin Nutr. 2013;67:1298–302.
doi: 10.1038/ejcn.2013.203
Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med [Internet]. 2020.;17(4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192386/ . Accessed 22 Mar 2021.
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–44.
doi: 10.1016/j.jhep.2018.10.033
Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23:1–12.
doi: 10.3350/cmh.2016.0109
Jamialahmadi O, Mancina RM, Ciociola E, Tavaglione F, Luukkonen PK, Baselli G. et al.Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease.Gastroenterology. 2020;160:1634–1646.e7. https://doi.org/10.1053/j.gastro.2020.12.023 . Epub 2021 Feb 6.
doi: 10.1053/j.gastro.2020.12.023
De Vincentis A, Mancina RM, Pihlajamäki J, Männistö V, Petta S, Dongiovanni P, et al. Genetic variants in the MTHFR are not associated with fatty liver disease. Liver Int.2020;40:1934–40.
doi: 10.1111/liv.14543
Vespasiani-Gentilucci U, Gallo P, Dell’Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol. 2018;24:4835–45.
doi: 10.3748/wjg.v24.i43.4835
Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283:356–70.
doi: 10.1111/joim.12719
Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31:35–45.
doi: 10.1016/j.cmet.2019.12.002
Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775–82.
doi: 10.1016/j.jhep.2020.11.024
De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol. 2021;S1542-3565:00595–4.
Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158–61.
doi: 10.1136/bmj.311.6998.158
Sluik D, Boeing H, Montonen J, Pischon T, Kaaks R, Teucher B, et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011;174:22–34.
doi: 10.1093/aje/kwr048
Kuk JL, Janiszewski PM, Ross R. Body mass index and hip and thigh circumferences are negatively associated with visceral adipose tissue after control for waist circumference. Am J Clin Nutr. 2007;85:1540–4.
doi: 10.1093/ajcn/85.6.1540